Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
46 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-175 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
14 |
Audentes Therapeutics Inc
Audentes Therapeutics Inc is a biotechnology company that specializes in the development and commercialization of gene therapies for the treatment of rare muscle diseases. The company is primarily focused on developing treatments for neuromuscular conditions such as spinal muscular atrophy (SMA) and myotonic dystrophy. Audentes aims to provide innovative and potentially life-changing therapies for patients with limited treatment options. They utilize advanced genetic engineering techniques to deliver functioning copies of genes to targeted cells, thereby restoring normal function and improving patient outcomes. The company was founded in 2012 and is headquartered in San Francisco, California. Audentes Therapeutics Inc has gained recognition for its groundbreaking research and commitment to addressing unmet medical needs in the field of rare diseases.
Company Address: 600 California Street, 17th Floor San Francisco 94108 CA
Company Phone Number: 818-1001 Stock Exchange / Ticker: NASDAQ BOLD
|